We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Image: A set of 31 tiny RNA markers (small noncoding RNAs) could help identify people at higher lung cancer risk before the disease is clinically detected (Image Credit: 123RF)

Blood RNA Panel Predicts Lung Cancer Risk Years Before Diagnosis

An RNA-based blood panel flags lung cancer risk up to 10 years before diagnosis with 95% accuracy More...
01 Oct 2026
Image: Schematic overview of the obtained results. (Carla Rojo, María Rullan, Miguel Sogbe, et al. eGastroenterology, 2026. doi:10.1136/ egastro-2026-100425)

Bile DNA Testing Detects Tumor Signals Before Conventional Cancer Diagnosis

New data show that bile-based DNA analysis detects cancer in biliary strictures and is more specific than a standard blood marker. More...
01 Oct 2026
Image Credit: iStock

New Blood Test Could Help Predict Severe Scoliosis in Adolescents

A new microRNA blood test predicts progression risk in adolescent idiopathic scoliosis. More...
01 Oct 2026
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Screening after invasive pneumococcal disease can uncover previously undiagnosed blood cancer and immune deficiency. More...
01 Oct 2026
Image Credit: 123RF

Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation

New data show a tumor test identifies prostate cancers more likely to benefit from hormone therapy with salvage radiotherapy. More...
01 Oct 2026
Image:Geographic distribution of the survey respondents. (Cavalier E, Kapoula G, Bhattoa HP, et al. IOF-IFCC international survey of global laboratory practices for bone status indices. Clin Chem Lab Med. 2026. DOI:10.1515/cclm-2026-0941.)

Global Survey Underscores Need to Standardize Bone Biomarker Testing

New data show variation across labs in bone marker testing, calling for harmonized reporting to improve clinical interpretation. More...
01 Oct 2026
Image: Developed and manufactured by Freenome and exclusively commercialized by Abbott, SimpleScreen CRC joins the Cologuard Plus test in Abbott’s screening portfolio, which now spans both stool‑ and blood‑based options (Photo courtesy of Freenome)

Blood-Based Test Broadens Colorectal Cancer Screening Options

An FDA-approved blood-based test detects colorectal cancer with 81% sensitivity and 90% specificity More...
01 Oct 2026
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Copyright © 2000-2026 Globetech Media. All rights reserved.